The Medical Management of Symptomatic Benign Prostatic Enlargement

Association of Urological Surgeons Website information page “prostate symptoms” http://www.baus.org.uk/patients/symptoms/luts.htm [accessed 20.03.12].

Emberton M , Anson K . Acute urinary retention in men: an age old problem. British Medical Journal 1999; 318: 921–5.

Cabelin MA , Te AE , Kaplan SA . Benign prostatic hyperplasia: challenges for the new millennium. Current Opinions in Urology 2000; 10: 301–6.

Kaplan SA . Factors in predicting failure with medical therapy for BPH. Reviews in Urology 2005; 7 (Suppl. 7): S34–9.

Andriole G , Bruchovsky N , Chung LWK , Matsumoto AM , Rittmaster R , Roehrborn C . Dihydrotestosterone and the prostate: the scientific rationale for 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Journal of Urology 2004; 172: 1399–403.

Enlarged vs normal prostate illustration. Available from http://www.meb.uni-bonn.de/Cancernet/CDR0000062965.html [accessed 25.03.12].

Barkin J . Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. The Canadian Journal of Urology 2011; 18 (Suppl.): 14–9.

Figure 2: International Prostate Symptom Score (IPSS) http://www.medscape.com/viewarticle/4717842 [accessed 21.03.12].

Rhodes T , Girman CJ , Jacobsen SJ , Roberts RO , Guess HA , Lieber MM . Longitudinal prostate growth rates during 5 years in randomly selected community of men aged 40 to 79 years old. Journal of Urology 1999; 161: 1174–9.

Speakman MJ , Kirby RS , Joyce A , Abrams P , Pocock R . Guideline for the primary care management of male lower urinary tract symptoms. British Journal of Urology International 2004; 93: 985–90.

Roehrborn CG , McConnell JD , Liaber M , Kaplan S , Geller J , Malek GH . Serum Prostate Specific antigen concentration is a powerful predictor of acute urinary retention and needed for surgery in men with clinical benign prostate hyperplasia. Urology 1999; 53: 473–80.

Emberton M , Andriole GL , de la Rosette J , Djavan B , Hoefner K , Vela Navarrete R . Benign prostatic hyperplasia: a progressive disease of ageing men. Journal of Urology 2003; 61: 267–73.

de la Rosette J , Alivizatos G , Madersbacher S , Rioja Sanz C , Nordline J , Emberton M . Guidelines on benign prostatic hyperplasia. European Association of Urology; 2008.

Nix JW , Carson CC . Medical management of benign prostatic hypertrophy. The Canadian Journal of Urology 2007; 14 (Suppl. 1): 53–7.

Milani D , Djavan B . Lower tract symptoms suggestive of benign prostatic hyperplasia; latest update on alpha-adreboceptor antagonists. British Journal of Urology International 2005; 95 (Suppl. 4): 29–36.

NICE guidelines 2010 for the management of lower urinary tract symptoms in men available from http://www.nice.org.uk/CG97 [accessed 21.03.12].

Kaplan S . Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. British Journal of Urology International 2008; 102 (Suppl. 2): 3–7.

Nickel JC , Gilling P , Tammela TL , Morrill B , Wilson TH , Rittmaster RS . Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). British Journal of Urology International 2001; 108(3): 388–94.

Roehrborn CG , Marks LS , Fenter T , Freedman S , Tuttle J , Gittleman M . Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709–15.

Roehrborn C , Heaton JPW . Medical management for BPH: the role of combination therapy. European Urology Supplements 2006; 5(12): 697–758.

Barkin J , Guimarães M , Jacobi G , Pushkar D , Taylor S , van Vierssen Trip OS . Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5areductase inhibitor dutasteride. European Journal of Urology 2003; 44: 461–610.

Roehrborn C , Siami P , Barkin J , Damiao R , Major-Walker K , Morrill B . The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Journal of Urology 2008; 179: 616–21.

Kaplan SA , Roehrborn CG , Abrams P , Chapple CR , Bavendam T , Guan Z . Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. International Journal of Clinical Practice 2011; 65(4): 487–507.

Wang C . Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Current Opinions in Urology 2010; 20(1): 49–54.

Laydner HK , Oliveira P , Oliveira CR , Makarawo TP , Andrade WS , Tannus M . Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. British Journal of Urology International 2010; 20(1): 49–54.

Dovey Z , Corbishley CM , Kirby RS . Prostatic intraepithelial neoplasia: a risk factor for prostate cancer. Canadian Journal of Urology 2005; 12 (Suppl. 1): 49–52, discussion 99-100.

Kirby M , Fitzpatrick J . Facilitating the medical management of benign prostatic hyperplasia in primary care. British Journal of Urology International 2009; 104(6): 751–3. September.